Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTX-568
- Development stage
- Preclinical
- Lead developer
- Lyntonix
- Modality
- Small Molecules
01
Overview
LTX-568 is a first-in-class small molecule antagonist of the serotonin type 7 receptor (5-HT7R) being developed by Lyntonix Biotech. It is specifically designed to treat visceral pain hypersensitivity associated with irritable bowel syndrome (IBS) and chronic abdominal pain. The drug exhibits high potency with a Ki value of less than 10nM and demonstrates over 100-fold selectivity against more than 160 other protein receptors. LTX-568 is characterized by its peripheral tissue selectivity and high water solubility (>10mg/mL), aiming to reduce visceral pain without significant central nervous system side effects. As of early 2024, it is in the preclinical stage, with IND-enabling GLP studies planned for 2025 and IND submissions to the US and Taiwan expected in 2026.
Beyond the preview
Go deeper on LTX-568.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTX-568.